Neutralizing antibodies against GCP‐2 (Verbeke et al. 2011), small molecule inhibitors for the CXCR1/CXCR2 receptors (Campbell et al. 2013), and for CREB (Xiao et al. 2010) have already been shown to reduce tumor progression in breast cancer (Ginestier et al. 2010). This evidence concerns the gene CXCL6 and breast carcinoma.